TRVN
Healthcare BiotechnologyTrevena, Inc.
$0.01
+0.00 +0.00% today
Price History
Not enough data
Key Stats
Market Cap
10,365.456
Avg Volume
90
EPS
-$52.75
52W High
$1.50
52W Low
$0.00
Div. Yield
0.0%
Valuation
Forward P/E
-0.00
P/B Ratio
-0.00
P/S Ratio
0.02
EV/EBITDA
-0.76
EV/Revenue
44.16
Margins
Gross Margin (190.5%)
Operating Margin (1970.7%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Revenue Growth (YoY)
57.2%
Return on Assets
(62.4%)
Liquidity & Leverage
Current Ratio
2.42
Quick Ratio
2.21
Total Cash
13.46M
Total Debt
37.56M
About
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
www.trevena.com